City Therapeutics Tests IPO Demand for an Early RNAi Pipeline

CAMBRIDGE, Mass., October 13, 2026 • City Therapeutics is bringing one of the more institutionally credible early-stage biotech offerings of the fall to market. The RNA interference developer is seeking about $175 million at the midpoint, backed by ARCH Venture Partners, Fidelity and a four-bank underwriting group, even though its lead wholly owned drug remains in Phase 1. That combination makes the deal a useful test of how much public investors will pay for pedigree, platform promise and near-term clinical readouts before efficacy data arrive.

The company today filed an 8-A registration for its common stock, another last-mile step toward trading on the Nasdaq Global Market under CTY. The preliminary prospectus offers 9,722,222 primary shares at $17 to $19, plus a 1,458,333-share underwriters’ option. At $18, City would raise $175 million gross and expects about $158.3 million net; the midpoint implies a post-offering equity value of roughly $906 million. Goldman Sachs and Jefferies are lead bookrunners, with Stifel also bookrunning and Oppenheimer as co-manager.

This is a financing for a concentrated clinical bet. CITY-FXI, a GalNAc-conjugated small interfering RNA aimed at Factor XI, is being developed for thromboembolic disease. In the first three single-ascending-dose cohorts in healthy volunteers, the company reported greater than 60% FXI knockdown at 15 mg, close to 80% at 50 mg and 85% three weeks after a 150 mg dose; it said the candidate was generally well tolerated in those cohorts. Additional Phase 1 data are expected late this year, followed by broader single-dose data in mid-2027 and a planned Phase 2 study in total knee arthroplasty beginning in mid-2027, according to the amended S-1.

IPOGrid reads those early knockdown results as a credible reason to engage with the story, but not yet as clinical validation. The measurements show target engagement, while the proposed investment case ultimately requires CITY-FXI to prevent thrombosis without adding unacceptable bleeding risk. The competitive field is substantial: City itself identifies programs from Bayer, Bristol Myers Squibb, Johnson & Johnson, Novartis, Regeneron, ADARx and others pursuing related thrombotic indications or Factor XI biology. The planned Phase 2 data are not expected until early 2028.

The rest of the pipeline broadens the number of shots, while adding execution demands. CITY-RBP4 is intended to reduce vitamin A delivery to the eye in Stargardt disease and is expected to enter Phase 1 in late 2026. CITY-TFR2, aimed at anemia associated with myelofibrosis, is slated for an investigator-initiated study in China late this year and a Phase 1/2 study in early 2027. City also has research collaborations with Bausch + Lomb in ocular disease and Biogen in central nervous system disease. These partnerships produced all of City’s $13.6 million of 2025 revenue and $6.4 million in the first half of 2026; the company has no approved products or product sales.

The financial texture is therefore closer to a well-funded research company than a commercial biotech. City lost $58.5 million in 2025, up from $27.8 million in 2024, and lost $53.4 million in the first six months of 2026. It held $169.6 million of cash at June 30 and estimated $141.9 million at September 30. Management says existing cash plus IPO proceeds should fund operations into late 2028. Our interpretation is that the proposed raise buys passage through several meaningful data points, including additional CITY-FXI Phase 1 results, initial CITY-RBP4 data and the planned CITY-FXI Phase 2 readout, but it does not remove the normal financing risk attached to a multi-program clinical buildout.

The private-market sponsorship gives the offering more shape. City raised $99.5 million in a Series B only four months ago, when Viking Global and Sofinnova joined a syndicate that included ARCH, Fidelity, Invus, Rock Springs and Regeneron Ventures, according to the company’s June financing announcement. ARCH owns 35.0% before the IPO and an indicated 26.7% afterward, while Fidelity holds 10.0% before and 7.6% afterward, assuming no additional purchases. A $30 million Biogen convertible note is also set to convert into about 2.1 million shares immediately before the offering at 85% of the assumed $18 IPO price.

Still, the prospectus does not disclose a directed-share program or named indications of interest from existing holders. The reviewer’s concern is that a strong cap table should not be mistaken for a visible cornerstone order in the IPO book. Public investors are being asked to establish the price at which early pharmacodynamic evidence, experienced RNAi leadership and multiple 2027 catalysts compensate for a roughly $1 billion valuation and years of clinical work ahead.

The setup is credible and the syndicate is strong. The decisive signal now is pricing: a deal at the top of the range would show that investors are willing to underwrite City’s platform and management pedigree before efficacy is established; a midpoint or lower outcome would suggest the market still demands a meaningful clinical-stage discount, even from one of the better-backed biotech issuers on the calendar.